| Name | Value | 
|---|---|
| Revenues | 8.3M | 
| Cost of Revenue | 1.9M | 
| Gross Profit | 6.3M | 
| Operating Expense | 14.4M | 
| Operating I/L | -22.0M | 
| Other Income/Expense | -12.7M | 
| Interest Income | 0.0M | 
| Pretax | -24.0M | 
| Income Tax Expense | -0.1M | 
| Net Income/Loss | -23.9M | 
Osmotica Pharmaceuticals plc is an integrated biopharmaceutical company that develops and commercializes a range of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include treatments for attention deficit hyperactivity disorder (ADHD), Parkinson's disease, drug-induced extrapyramidal reactions, multiple sclerosis spasticity, Blepharoptosis, and neurodegenerative disorders. Additionally, it offers women's health products and a variety of non-promoted products for conditions such as major depressive disorders, hypertension, overactive bladder, pain management, and urinary tract infections.